Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|22 CitationsHormonal & GHFemale-friendly

Tesamorelin Dosing Protocol: GHRH Analog Research

Also known as: Egrifta, Trans-3-Hexenoyl-GHRH (1-44), Visceral Fat GHRH

Dose Range
1–2 mgResearch range
0Typical research window: 1–2 mg2.5 mg

Studied in human Phase 3 clinical trials — not medical advice. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg) SubQ once daily; research protocols evaluate 1–2 mg daily.

Protocol at a Glance
How Often
Daily

Once daily SubQ (typically before bed, ≥90 min after food)

A Typical Run
8–16 weeks

FDA approval context: daily use. Research protocols commonly run 8–16 weeks followed by a 4-week washout.

How It's Taken
Vial

SubQ injection (abdomen)

Evidence
Established

Phase 3 human RCTs & FDA-approved formulation (Egrifta)

Half-Life & 72-Hour Clearance Shape
~8–11 min

~8–11 min (FDA labels: 8 min for Egrifta SV, 11 min for Egrifta WR, healthy subjects)

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

10 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 5 mg in every mL (50 mcg per unit)
0u10u20u30u40u50u
Low end: 1 mg20 units
High end: 2 mg40 units

All U-100: 100 units = 1 mL. 10 doses in the vial at the low end (5 doses at the high end).

Track the doses you run

Save Tesamorelin to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

Verified Peptide Vial Suppliers · Sorted by Real $/mg•Checked Nov 11, 2026

Tesamorelin supplier & $/mg comparison.

Source:
Max $/mg:
Sort:
Ascension Peptides50% OFF AUTO-APPLIED
Batch COAs (Kovera Labs, MZ Biolabs) on product page
US Domestic Vial
50% Off First Order Link
$25.00 net$50.00
5mg Lyophilized Vial
$5.00/mg$10.00/mg retail
Polaris Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$65.00
10mg vial
$6.50/mg
Bulletproof BioLabs
ILS Laboratories HPLC COA COA-2026-WMOYJM, lot BPB-2610-001
US Domestic Vial
Vendor-supplied list price (Nov 7, 2026; store requires login)
$72.00
10mg vial
$7.20/mg
Biotech Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$73.00
10mg vial
$7.30/mg
Core Peptides
COA per store product page
US Domestic Vial
List price (verified Oct 31)
$79.00
10mg vial
$7.90/mg
Direct Peptides
COA per store product page
US Domestic Vial
List price (last verified Nov 4, 2026; store now requires sign-in)
$79.00
10mg vial
$7.90/mg
Swift Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026)
$164.99
20mg vial
$8.25/mg
Elite Research USA
Batch COA on product page
US Domestic Vial
List price
$85.00
10mg vial
$8.50/mg
Pure Peptides
COA per store product page
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDE9544 takes 10% off at checkout
$43.00
5mg vial
$8.60/mg
Peptyes
Horizon Analytical UPLC-MS COA, lot DPS-1572576 (99.61%); COA names Privilege Bio Labs (Peptyes says: its manufacturer)
US Domestic Vial
List price (verified Nov 11, 2026); code PEPTIDEPROTOCOLS takes 10% off at checkout
$114.00
10mg vial
$11.40/mg
Limitless Peptides
COA per store product page
US Domestic Vial
Code: PEPTIDEPROTOCOLS
$140.00
10mg vial
$14.00/mg
Sorted strictly by calculated $/mg or 2026 COA score. Only research peptide vial suppliers are included in $/mg benchmarks.
Full Verified $/mg Index →

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

FDA-Approved MedicationTier 1 — Human Phase 3 RCT / Approved
Pharmacological Class
Pituitary Growth Hormone Secretagogue (GHRH Analog / Ghrelin Receptor Agonist)
Administration Route
Under-the-skin injection (Subcutaneous)
2026 FDA & 503A Status
FDA-approved GHRH analog (Egrifta SV) for visceral adipose reduction; also accessible via licensed 503A physician telehealth clinics and third-party COA-verified analytical reference vials.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S2.2 (Peptide Hormones, Growth Factors, GH Fragments, BPC-157 & Thymosin-β4)
Evidence Tier
Tier 1 — Human Phase 3 RCT / Approved: Multi-center randomized controlled human clinical trials (Phase 3) and/or regulatory approval
What is a Growth Hormone Secretagogue?

A compound that stimulates your pituitary gland to release more of its own growth hormone (GH). Unlike synthetic GH injection, secretagogues trigger natural pulsatile GH release. Examples: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin. MK-677 (Ibutamoren) is technically not a peptide but acts as an oral GH secretagogue.

Tesamorelin is the same active compound as Egrifta, Egrifta SV (Theratechnologies). FDA approved for: HIV-associated lipodystrophy.

Bottom Line Up Front

Tesamorelin is an FDA-approved GHRH analog for HIV-associated lipodystrophy. It reduces visceral adipose tissue (VAT) in HIV patients. The only FDA-approved GHRH analog for a specific indication.

Best evidence for

HIV-associated lipodystrophy, visceral fat reduction

Weakest evidence for

General weight loss in healthy individuals

Pharma equivalent

Egrifta (Theratechnologies)

Studies on file

22 (22 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Tesamorelin is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates endogenous growth hormone production. It is FDA-approved for HIV-associated lipodystrophy and has been studied for reducing visceral adipose tissue.

Mechanisms of Action

  • Stimulates pituitary release of growth hormone
  • Increases IGF-1 levels
  • Reduces visceral adipose tissue
  • Preserves subcutaneous fat
  • Improves lipid profiles

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
HIV Lipodystrophy Protocol
published study
2 mgDaily26 weeksSubcutaneoushuman
Baseline & Mid-Cycle Biomarker Bloodwork Panel

GH / IGF-1 & Glycemic Sensitivity Biomarker Panel (Tesamorelin)

Growth hormone secretagogues and somatomedin analogs directly elevate hepatic IGF-1 and can shift fasting insulin sensitivity via GH counter-regulatory signaling.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

Serum IGF-1 (LC/MS) + Z-Score

Day 0 + Wk 6–8

Why track at baseline: Establishes baseline somatotropic output before pituitary or local IGF-1R stimulation.

Week 6–8 check: Confirm physiological upper-quartile elevation (typically +30% to +80% above baseline) without supraphysiological overshoot (>300 ng/mL).

Fasting Insulin & HOMA-IR

Day 0 + Wk 6–8

Why track at baseline: Pituitary GH pulses promote free fatty acid mobilization, which can transiently reduce peripheral insulin sensitivity.

Week 6–8 check: Keep Fasting Insulin <6–8 uIU/mL; if elevated, enforce strict 2–3 hr pre-bed fasting before GH secretagogue administration.

HbA1c & Fasting Plasma Glucose

Day 0 + Wk 6–8

Why track at baseline: Screens for subclinical prediabetes prior to growth-factor or secretagogue exposure.

Week 6–8 check: Verify stable 90-day glycemic control (HbA1c <5.4% optimal) at Week 6–8.

hs-CRP, Prolactin & CMP

Day 0 + Wk 6–8

Why track at baseline: Checks systemic inflammation, pituitary selectivity (no off-target prolactin/cortisol rise), and hepatic/renal clearance.

Week 6–8 check: Confirm Ipamorelin/CJC/Tesamorelin selectivity with unchanged Prolactin and normal liver transaminases.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

22 Human

Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care.

Limitations: No placebo control reported. Review article — no new primary data.

2026|Journal of the American Academy of Orthopaedic Surgeons. Global research &amp; reviews
PubMed

BPC-157 demonstrated potential benefits in tendon and muscle repair, but these findings are largely unvalidated in human trials. A single human case series reported improvements in pain after intra-articular knee injections of BPC-157, although significant methodological flaws and a lack of controls limit its applicability and reliability.

Limitations: No placebo control reported. Review article — no new primary data.

2026|The American journal of sports medicine
PubMed

Seventy-three participants were randomized 3:2 to tesamorelin or SOC (2&#x2005;mg subcutaneously daily). The primary outcome was the change in neurocognitive performance at 6 months, with secondary outcomes including WC, mood, and daily functioning.

Limitations: Standard limitations apply. Check original paper for full discussion.

2025|The Journal of infectious diseases
PubMed

Among 38 participants on INSTI-based regimens at baseline, 15 individuals on tesamorelin and 16 individuals on placebo completed the 12-month study. Tesamorelin led to significant declines in visceral fat (median [interquartile range]: -25 [-93, -2] vs.

Limitations: Standard limitations apply. Check original paper for full discussion.

2024|AIDS (London, England)
PubMed

Through improved recognition of the lipodystrophy disorders, patients (and their affected family members) can be appropriately screened for cardiometabolic, noncardiometabolic, and syndromic abnormalities and undergo treatment with targeted interventions. Notably, insights gained through the study of this rare and extreme phenotype can inform our knowledge of more common disorders of adipose tissue overload, including generalized obesity.

Limitations: No placebo control reported. Case study — cannot establish causation.

2022|The Journal of clinical endocrinology and metabolism
PubMed

Participants (193 responders, 148 placebo) were 87% male and 83% white. Baseline characteristics were similar across arms, including VAT (-91 HU both arms, P&#x200a;=&#x200a;0.80) and SAT density (-94 HU tesamorelin, -95 HU placebo, P&#x200a;=&#x200a;0.29).

Limitations: Standard limitations apply. Check original paper for full discussion.

2021|AIDS (London, England)
PubMed

Notably, among tesamorelin-treated participants, these changes in hepatic expression correlated with improved fibrosis-related gene score. Our findings inform our knowledge of the biology of pulsatile growth hormone action and provide a mechanistic basis for the observed clinical effects of tesamorelin on the liver.

Limitations: Standard limitations apply. Check original paper for full discussion.

2021|JCI insight
PubMed

CSF1, a regulator of monocyte recruitment and activation, may serve as an innovative therapeutic target for NAFLD in HIV. Clinical Trials Registry Number: NCT02196831.

Limitations: Standard limitations apply. Check original paper for full discussion.

2021|Scientific reports
PubMed

61 patients were enrolled between Aug 20, 2015, and Jan 16, 2019, of whom 30 received tesamorelin and 30 received placebo. Patients receiving tesamorelin had a greater reduction of HFF than did patients receiving placebo, with an absolute effect size of -4&#xb7;1% (95% CI -7&#xb7;6 to -0&#xb7;7, p=0&#xb7;018), corresponding to a -37% (95% CI -67 to -7, p=0&#xb7;016) relative reduction from baseline.

Limitations: Standard limitations apply. Check original paper for full discussion.

2020|The lancet. HIV
PubMed

At baseline, serum log10 FGF21 was significantly associated with log10 liver fat (r=0.32, p=0.03). Log10 FGF21 tended to decrease in the tesamorelin group compared to placebo (p=0.06).

Limitations: Standard limitations apply. Check original paper for full discussion.

2018|Growth hormone &amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
PubMed

At baseline, VAT was positively associated with ALT (P&#x200a;=&#x200a;0.01). In study participants assigned to tesamorelin with baseline ALT or AST more than 30&#x200a;U/l, VAT responders experienced greater reductions in ALT (-8.9&#x200a;&#xb1;&#x200a;22.6 vs.

Limitations: Standard limitations apply. Check original paper for full discussion.

2018|AIDS (London, England)
PubMed

Plasma clearance and its interindividual variability [% coefficient of variation (CV)] was estimated to be 1,060&#xa0;L/h (33.6&#xa0;%). Volume of distribution was calculated to be 200&#xa0;L (17.7&#xa0;%).

Limitations: No placebo control reported.

2015|Clinical pharmacokinetics
PubMed

Effective therapeutic strategies can be challenging due to an increase risk of drug interactions and other comorbidities. Understanding the underlying pathophysiology and the principles of pharmacological and non-pharmacological therapeutic interventions can be of value in the appropriate management of dyslipidemia in the HIV-infected patient.

Limitations: No placebo control reported. Review article — no new primary data.

2015|Current atherosclerosis reports
PubMed

arthralgia, headache and peripheral oedema). Although long-term clinical experience is needed to further assess the benefits and risks of therapy, current evidence suggests that tesamorelin may be useful for reducing visceral adiposity in patients with HIV-associated lipodystrophy, thereby potentially improving self image.

Limitations: No placebo control reported. Review article — no new primary data.

2012|Drugs
PubMed

arthralgia, headache and peripheral edema). Although long-term clinical experience is needed to further assess the benefits and risks of therapy, current evidence suggests that tesamorelin may be useful for reducing visceral adiposity in patients with HIV-associated lipodystrophy, thereby potentially improving self image.

Limitations: No placebo control reported. Review article — no new primary data.

2012|BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
PubMed

Tesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26-52 weeks of treatment. Potential limitations for its use include high cost and lack of long-term safety and adherence data.

Limitations: No placebo control reported. Review article — no new primary data.

2012|The Annals of pharmacotherapy
PubMed

In addition to the medical management of metabolic syndrome and the sometimes surgical treatment of lipodystrophy, recombinant leptin provides hope for genetically determined lipodystrophy syndromes, whereas modifications in antiretroviral treatment and tesamorelin, a GHRH analog, is effective in the metabolic syndrome of HIV patients. Other therapeutic options will undoubtedly be developed, dependent on pathophysiological advances, which today tend to classify genetically determined lipodystrophy as being related to laminopathy or to lipid droplet disorders.

Limitations: No placebo control reported. Review article — no new primary data.

2012|Annales d'endocrinologie
PubMed

Compared with tesamorelin nonresponders, responders experienced greater mean (&#xb1;SD) reduction in triglyceride levels (26.

Limitations: Standard limitations apply. Check original paper for full discussion.

2012|Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
PubMed

Tesamorelin.

Human Study

In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono), a growth hormone-releasing factor analogue, was approved by the US Food and Drug Administration for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

Limitations: No placebo control reported.

2011|Nature reviews. Drug discovery
PubMed

At baseline, VAT was significantly associated with PAI-1 antigen (&#x3c1; = 0.36, P < 0.001), tPA antigen (&#x3c1; = 0.29, P < 0.001), CRP (&#x3c1; = 0.18, P < 0.001), and adiponectin (&#x3c1; = -0.22, P < 0.001). Treatment with tesamorelin resulted in a significant decrease from baseline in tPA antigen (-2.2 &#xb1; 2.5 vs.

Limitations: Standard limitations apply. Check original paper for full discussion.

2011|AIDS (London, England)
PubMed

A multicenter, randomized, placebo-controlled, Phase III clinical trial suggested that tesamorelin might be a beneficial treatment strategy for HIV-related lipodystrophy with a good safety profile and a positive effect on reducing visceral fat. Other potential indications for tesamorelin appear less promising from the current data.

Limitations: Review article — no new primary data.

2009|Expert opinion on investigational drugs
PubMed

Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.

Limitations: No placebo control reported. Review article — no new primary data.

2006|Current opinion in investigational drugs (London, England : 2000)
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •May increase risk of diabetes
  • •Fluid retention possible
  • •Carpal tunnel syndrome reported
  • •Requires daily injections
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get Tesamorelin, baseline labs & clinician oversight.

Full Tesamorelin $/mg comparison →
50% OFF AUTO-APPLIED$5.00/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR

Where to buy Tesamorelin: best verified price

Prices checked Nov 11, 2026 · sorted by $/mg · RUO

  1. 1. Ascension Peptides — $5.00/mg (5mg Lyophilized Vial, $25.00)
  2. 2. Polaris Peptides — $6.50/mg (10mg vial, $65.00)
  3. 3. Bulletproof BioLabs — $7.20/mg (10mg vial, $72.00)

Where is the cheapest place to buy Tesamorelin?

As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Ascension Peptides at $5.00/mg (5mg Lyophilized Vial, $25.00 after the 50% new-customer partner-link discount). We compared 11 US suppliers with live, checked prices.

How much does Tesamorelin cost per mg?

Verified US domestic prices currently range from $5.00/mg to $14.00/mg depending on supplier and vial size. Larger vials usually lower the $/mg.

How are these prices verified?

Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.

Is Tesamorelin approved for human use?

Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.

All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet

FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.